

**Report From Agency**

**STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD**

---

**IN THE MATTER OF RULEMAKING :  
PROCEEDINGS BEFORE THE : REPORT TO THE LEGISLATURE  
CONTROLLED SUBSTANCES BOARD : CR 22-037  
:  
:**

---

**I. THE PROPOSED RULE:** The proposed rule, including the analysis and text, is attached.

**II. REFERENCE TO APPLICABLE FORMS:** N/A

**III. FISCAL ESTIMATE AND EIA:** The Fiscal Estimate and EIA is attached.

**IV. DETAILED STATEMENT EXPLAINING THE BASIS AND PURPOSE OF THE PROPOSED RULE, INCLUDING HOW THE PROPOSED RULE ADVANCES RELEVANT STATUTORY GOALS OR PURPOSES:**

This rule schedules Embutramide as a Schedule III controlled substance. The Controlled Substances Board did not receive an objection to similarly listing Embutramide as a schedule III under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Embutramide as a schedule III controlled substance.

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Embutramide under chapter 961, Stats. by creating the following:

*CSB 2.87 Addition of Embutramide to schedule III. Section 961.18 (3) (bm), Stats., is created to read: 961.18 (3) (bm) Embutramide.*

The Affirmative Action order, dated July 9, 2021, took effect on July 19, 2021, when it was published in the Administrative Register and expires upon promulgation of a final rule.

**V. SUMMARY OF PUBLIC COMMENTS AND THE BOARD'S RESPONSES, EXPLANATION OF MODIFICATIONS TO PROPOSED RULES PROMPTED BY PUBLIC COMMENTS:**

Per s. 961.11(4), Stats., if no objection is made, the board shall promulgate a final rule for which notice of proposed rulemaking is omitted. Therefore, the Board did not hold a public hearing.

**VI. RESPONSE TO LEGISLATIVE COUNCIL STAFF RECOMMENDATIONS:**  
Legislative Council staff did not make any recommendations.

**VII. REPORT FROM THE SBRRB AND FINAL REGULATORY FLEXIBILITY ANALYSIS: N/A**